Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
The anti-PD-L1/CTLA-4 bispecific antibody KN046 plus lenvatinib in ...
The anti-PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab ...
a Cell uptake of KN046 (green) co-incubated with B16F10 cells at 1 h ...
Safety and Efficacy of KN046 in Combination with KN026 in Patients with ...
Associations of PD-L1 and CD8 expression with response to KN046 ...
The Results of Phase I Clinical Study of KN046 were published in ...
The Results of Phase II Clinical Study of KN046 in Combination with Nab ...
The Results of Phase II Clinical Study of KN046 in NSCLC were published ...
JSKN016-Alphamab Oncology
肿瘤医院最新成果：低剂量131I和KN046“强强联合”提升免疫治疗应答率
ASCO中国之声丨北肿沈琳团队研究：KN026联合KN046治疗局部晚期不可切除或转移性HER2阳性其他实体瘤的疗效和安全性-肿瘤瞭望
Use of [¹³¹I]-KN046 for noninvasive assessment and enhanced antitumor ...
KN046, a bispecific antibody against PD-L1 and CTLA-4, plus ...
Schematic illustration of the formation of KN046@¹⁹F‐ZIF‐8 nanoplatform ...
KN046-Alphamab Oncology
(PDF) Phase I trial of KN046, a novel bispecific antibody targeting PD ...
(PDF) Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in ...
Hung Trinh: The efficacy and safety of anti-PD-L1/CTLA-4 bispecific ...
Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 ...
Phase I trial of KN046, a novel bispecific antibody targeting PD-L1 and ...
Efficacy and safety of KN026, a bispecific anti-HER2 antibody, in ...
Table 1 from KN046, a bispecific antibody against PD-L1 and CTLA-4 ...
KN046-康宁杰瑞
Figure 1 from KN046, a bispecific antibody against PD-L1 and CTLA-4 ...
Table 2 from KN046, a bispecific antibody against PD-L1 and CTLA-4 ...
(PDF) 339 Preliminary safety, tolerability and efficacy results of ...
Table 3 from KN046, a bispecific antibody against PD-L1 and CTLA-4 ...
KN026-康宁杰瑞生物制药有限公司
339 Preliminary safety, tolerability and efficacy results of KN026 (a ...
Characterization of KN046@¹⁹F‐ZIF‐8. a) SEM image of KN046@¹⁹F‐ZIF‐8 ...
KN026+KN046-Alphamab Oncology
Alphamab Oncology Announced IND Approval of PD-L1/OX40 Bispecific ...
KN019-Alphamab Oncology | Alphamab Biopharmaceuticals Co.,Ltd.
a Initial labeling yield of [¹³¹I]-KN046 placed for 30 min at room ...
First-line treatment with KN046, chemotherapy and palliative ...
康宁杰瑞KN026+KN046免疫疗法获CDE批准III期临床，用于治疗HER2阳性晚期胃癌医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
(A). Schematic diagram of the structural composition of KN046@19 F ...
SABCS中国之声丨刘洁琼教授团队：KN046＋KN026两种双抗联合治疗晚期HER2阳性乳腺癌的单细胞测序分析结果_患者_研究_临床
J Immunother Cancer. 新型双特异性抗体KN046在晚期实体瘤患者中的I期试验 – 阔然基因 | 阔然生物
ASCO中国之声丨北肿沈琳团队研究：KN026联合KN046治疗局部晚期不可切除或转移性HER2阳性其他实体瘤的疗效和安全性医药新闻 ...
康宁杰瑞HER2双表位ADC分析 康宁杰瑞KN046治疗晚期鳞状sqNSCLC的临床III期临床，OS暂未达到统计学显著性差异未能成功揭盲 ...
KN046联合化疗一线治疗转移性非小细胞肺癌研究结果在Cell子刊全文发表-康宁杰瑞
2021 ASCO丨KN046联合AG一线治疗转移性胰腺癌疗效显著！ - 知乎
我想了解一下KN046的三种特异性作用机制的真实信息_行行查_行业研究数据库
康宁杰瑞KN046联合白蛋白结合型紫杉醇一线治疗晚期三阴乳腺癌研究结果在Nature子刊全文发表医药新闻-ByDrug-一站式医药资源共享中心 ...
康宁杰瑞KN046联合白蛋白结合型紫杉醇一线治疗晚期三阴乳腺癌研究结果在Nature子刊全文发表-康宁杰瑞
康宁杰瑞公布PD-L1/CTLA-4双抗KN046及KN026的4项最新数据医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
【3923】新型双特异性抗体KN046联合化疗一线治疗mTNBC获得生存获益医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Nat. Commun：抗PD-L1/CTLA-4双特异性抗体KN046联合白蛋白结合型紫杉醇一线治疗转移性三阴性乳腺癌：多中心II期试验 ...
中国国产原研第二代免疫双抗药,双特异性抗体药物KN046联合白蛋白紫杉醇治疗转移性三阴性乳腺癌患者无进展生存7.3个月_全球肿瘤医生网
KN046联合化疗一线治疗转移性非小细胞肺癌研究结果在Cell子刊全文发表-美通社PR-Newswire
康宁杰瑞双特异性抗体KN046启动临床Ⅲ期试验，研究者会议圆满召开-搜狐大视野-搜狐新闻
Full article: Cadonilimab, a tetravalent PD-1/CTLA-4 bispecific ...
KN046两项治疗晚期非小细胞肺癌的更新研究数据公布
要来了！双康引领的双抗大战即将开始-试药员招聘与临床试验信息平台
国内PD-1/CTLA-4抗体技术及最新数据汇总 - 知乎
PD-L1/CTLA-4双特异性抗体KN046两项临床研究数据
Towards treating all stages of gastric cancer and gastroesophageal ...
KN046联合化疗一线治疗转移性非小细胞肺癌研究结果在Cell子刊全文发表医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
双抗药物有哪些,两个靶点的抗癌药物,疗效一定比单个靶点的更好吗-无癌家园
KN046和AK104联合仑伐在肝癌领域机制及效果比较 ——抗血管生成药物与ICIs的作用机制——我们常说的抗血管生成药物主要有3类：大分子单 ...
SABCS中国之声丨刘洁琼教授团队：KN046＋KN026两种双抗联合治疗晚期HER2阳性乳腺癌的单细胞测序分析结果医药新闻-ByDrug-一 ...
Design and Efficacy of a Monovalent Bispecific PD-1/CTLA4 Antibody That ...
.png)
